Identification In Silico and In Vitro of Novel Trypanosomicidal Drug-Like Compounds

Chemical Biology and Drug Design

Volumn 80, Issue 1, 2012, Pages 38-45

  Castillo Garit, Juan A ^a,b   Del Toro Cortés, Oremia ^a   Kouznetsov, Vladimir V ^c   Puentes, Cristian Ochoa ^d   Romero Bohórquez, Arnold R ^c   Vega, Maria C ^e   Rolón, Miriam ^e   Escario, José A ^f   Gómez Barrio, Alicia ^f   Marrero Ponce, Yovani ^a,b   Torrens, Francisco ^b   Abad, Concepción ^b  

^a CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^d UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^e CENTRO PARA EL DESARROLLO DE LA INVESTIGACIÓN CIENTÍFICA   (Paraguay)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Anti epimastigote elimination; Atom based bilinear indices; Cytotoxicity; Trypanosoma cruzi; Trypanosomicidal; Virtual screening

Indexed keywords

ANTITRYPANOSOMAL AGENT; CRIS 105; CRIS 109; CRIS 110; CRIS 111; CRIS 112; CRIS 116; CRIS 119; CRIS 130; CRIS 131; CRIS 135; CRIS 140; CRIS 141; CRIS 142; CRIS 143; CRIS 147; CRIS 148; CRIS 149; CRIS 153; NIFURTIMOX; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; EPIMASTIGOTE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; VIRTUAL REALITY;

ANIMALS; CELL LINE; CELL SURVIVAL; DISCRIMINANT ANALYSIS; MICE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 84862122369     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01378.x     Document Type: Article

References (47)

1. WHO (2002) Control of Chagas' disease. Second Report of the WHO Expert Committee. Geneva: WHO. Tech. Rep. Ser; p. 1-109.
2. Gilbert I.H. (2002) Inhibitors of dihydrofolate reductase in leishmania and trypanosomes. Biochim Biophys Acta;1587:249-257.
3. World Health Organization(TDR/GTC/09 2007) Reporte sobre la enfermedad de Chagas. Grupo de trabajo científico. Ginebra: World Health Organization.
4. Marin-Neto J.A., Cunha-Neto E., Maciel B.C., Simoes M.V. (2007) Pathogenesis of chronic Chagas heart disease. Circulation;115:1109-1123.
5. PAHO (2007) Health in the Americas 2007. In: Regional s.a.t.p., editor. Health in the Americas 2007. Washington, DC: Pan American Health Organization, p. 1-3.
6. Gascón J. (2005) Diagnóstico y tratamiento de la Enfermedad de Chagas importada. Med Clín;125:230-235.
7. Gascon J., Bern C., Pinazo M.-J. (2010) Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop;115:22-27.
8. Schmunis G.A., Yadon Z.E. (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop;115:14-21.
9. Dias J.P., Bastos C., Araujo E., Mascarenhas A.V., MartinsNetto E., Grassi F., Silva M., Tatto E., Mendonca J., Araujo R.F., Shikanai-Yasuda M.A., Aras R. (2008) Acute Chagas disease outbreak associated with oral transmission. Rev Soc Bras Med Trop;41:296-300.
10. Prata A. (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis;1:92-100.
11. Cerecetto H., Gonzalez M. (2002) Chemotherapy of Chagas' disease: status and new developments. Curr Top Med Chem;2:1187-1213.
12. Roldos V., Nakayama H., Rolón M., Montero-Torres A., Trucco F., Torres S. et al. (2008) Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem;43:1797-1807.
13. Urbina J.A. (2002) Chemotherapy of Chagas disease. Curr Pharm Des;8:287-295.
14. Viotti R., Vigliano C., Lococo B., Alvarez M.G., Petti M., Bertocchi G. et al. (2009) Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther;7:157-163.
15. Cavalli A., Bolognesi M.L. (2009) Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J Med Chem;52:7339-7359.
16. DiMasi J.A., Hansen R.W., Grabowski H.G. (2003) The price of innovation: new estimates of drug development costs. J Health Econ;22:151-185.
17. Marrero-Ponce Y., Castillo-Garit J.A., Torrens F., Romero-Zaldivar V., Castro E. (2004) Atom, atom-type, and total linear indices of the "molecular pseudograph's atom adjacency matrix": application to QSPR/QSAR studies of organic compounds. Molecules;9:1100-1123.
18. Marrero-Ponce Y., Meneses-Marcel A., Rivera-Borroto O., García-Domenech R., de Julián-Ortiz J., Montero A. et al. (2008) Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds. J Comput Aided Mol Des;22:523-540.
19. Marrero-Ponce Y., Torrens F., Alvarado Y.J., Rotondo R. (2006) Bond-based global and local (bond, group and bond-type) quadratic indices and their applications to computer-aided molecular design. 1. QSPR studies of diverse sets of organic chemicals. J Comput Aided Mol Des;20:685-701.
20. Marrero-Ponce Y., Khan M.T.H., Casañola-Martín G.M., Ather A., Sultankhodzhaev M.N., Torrens F. et al. (2007) Prediction of tyrosinase inhibition spectra for chemicals using novel atom-based bilinear indices. ChemMedChem;2:449-478.
21. Castillo Garit J.A., Martinez-Santiago O., Marrero Ponce Y., Casañola-Martin G.M., Torrens F. (2008) Atom-based non-stochastic and stochastic bilinear indices: application to QSPR/QSAR studies of organic compounds. Chem Phys Lett;464:107-112.
22. Castillo-Garit J.A., Marrero-Ponce Y., Escobar J., Torrens F., Rotondo R. (2008) A novel approach to predict aquatic toxicity from molecular structure. Chemosphere;73:415-427.
23. Castillo-Garit J.A., Marrero-Ponce Y., Torrens F., García-Domenech R. (2008) Estimation of ADME properties in drug discovery: predicting caco-2 cell permeability using atom-based stochastic and non-stochastic linear indices. J Pharm Sci;97: 1946-1976.
24. Castillo-Garit J.A., Vega M.C., Rolon M., Marrero-Ponce Y., Kouznetsov V., Torres D.F. et al. (2010) Computational discovery of novel trypanosomicidal drug-like chemicals by using bond-based non-stochastic and stochastic quadratic maps and linear discriminant analysis. Eur J Pharm Sci;39:30-36.
25. Castillo-Garit J.A., Vega M.C., Rolón M., Marrero-Ponce Y., Gómez-Barrio A., Escario J.A. et al. (2011) Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support. Eur J Med Chem;46:3324-3330.
26. Marrero-Ponce Y., Castillo-Garit J.A. (2005) 3D-chiral atom, atom-type, and total non-stochastic and stochastic molecular linear indices and their applications to central chirality codification. J Comput Aided Mol Des;19:369-383.
27. Marrero-Ponce Y., Castillo-Garit J.A., Castro E.A., Torrens F., Rotondo R. (2008) 3D-chiral (2.5) atom-based TOMOCOMD-CARDD descriptors: theory and QSAR applications to central chirality codification. J Math Chem;44:755-786.
28. Castillo-Garit J.A., Marrero-Ponce Y., Torrens F. (2006) Atom-based 3D-chiral quadratic indices. Part 2: prediction of the corticosteroid-binding globulinbinding affinity of the 31 benchmark steroids data set. Bioorg Med Chem;14:2398-2408.
29. Castillo-Garit J.A., Marrero-Ponce Y., Torrens F., García-Domenech R., Rodríguez-Borges J.E. (2009) Applications of bond-based 3D-chiral quadratic indices in QSAR studies related to central chirality codification. QSAR Comb Sci;28:1465-1477.
30. Castillo-Garit J.A., Marrero-Ponce Y., Torrens F., García-Domenech R., Romero-Zaldivar V. (2008) Bond-based 3D-chiral linear indices: theory and QSAR applications to central chirality codification. J Comput Chem;29:2500-2512.
31. Castillo-Garit J.A., Marrero-Ponce Y., Torrens F., Rotondo R. (2007) Atom-based stochastic and non-stochastic 3D-chiral bilinear indices and their applications to central chirality codification. J Mol Graph Model;26:32-47.
32. Marrero-Ponce Y., Meneses-Marcel A., Castillo-Garit J.A., Machado-Tugores Y., Escario J.A., Gómez-Barrio A. et al. (2006) Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs. Bioorg Med Chem;14:6502-6524.
33. Kier L.B., Hall L.H. (1986) Molecular Connectivity in Structure-Activity Analysis. Letchworth, UK: Research Studies Press.
34. Todeschini R., Gramatica P. (1998) New 3D molecular descriptors: the WHIM theory and QSAR applications. Perspect Drug Disc Des;9-11:355-380.
35. Consonni V., Todeschini R., Pavan M. (2002) Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. J Chem Inf Comput Sci;42:682-692.
36. Pauling L. (1939) The Nature of Chemical Bond. Ithaca, NY: Cornell University Press.
37. Baldi P., Brunak S., Chauvin Y., Andersen C.A., Nielsen H. (2000) Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics;16:412-424.
38. Silva L.H., Nussensweig V. (1953) Sobre uma cepa Trypanosoma cruzi virulenta para o camundongo branco. Folia Clin Biol;20:191-207.
39. Gómez-Barrio A., Martínez-Díaz R.A., Atienza J., Escario J.A., Diego C., Avendaño C. (1997) New derivatives of gentian violet as trypanocides: in vitro and in vivo assays on Trypanosoma cruz. Res Rev Parasitol;57:25-31.
40. Rolón M., Vega C., Escario J., Gómez-Barrio A. (2006) Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes. Parasitol Res;99:103-107.
41. Rolón M., Seco E.M., Vega C., Nogal J.J., Escario J.A., Gómez-Barrio A. et al. (2006) Selective activity of polyene macrolides produced by genetically modified Streptomyces on Trypanosoma cruzi. Int J Antimicrob Agents;28:104-109.
42. Estrada E., Peña A. (2000) In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem;8:2755-2770.
43. Estrada E., Uriarte E., Montero A., Teijeira M., Santana L., De Clercq E. (2000) A novel approach for the virtual screening and rational design of anticancer compounds. J Med Chem;43:1975-1985.
44. Marrero-Ponce Y., Castillo-Garit J.A., Olazabal E., Serrano H.S., Morales A., Castanedo N. et al. (2005) Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic. Bioorg Med Chem;13:1005-1020.
45. Estrada E. (1999) Novel Strategies in the Search of Topological Indices. In: Devillers J., Balaban A.T., editors. Topological Indices and Related Descriptors in QSAR and QSPR. Amsterdam: Gordon and Breach: p. 503-553.
46. Tropsha A., Gramatica P., Gombar V.K. (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci;22:69-77.
47. Meneses-Marcel A., Rivera-Borroto O.M., Marrero-Ponce Y., Montero A., Machado Tugores Y., Escario J.A. et al. (2008) New antitrichomonal drug-like chemicals selected by bond (edge)-based TOMOCOMD-CARDD descriptors. J Biomol Screen;13:785-794.